{
	"@context": {
		"rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
		"dct": "http://purl.org/dc/terms/",
		"owl": "http://www.w3.org/2002/07/owl#",
		"xsd": "http://www.w3.org/2001/XMLSchema#",
		"rdfs": "http://www.w3.org/2000/01/rdf-schema#",
		"@vocab": "http://ld.nice.org.uk/ns/bnf#",
		"bnf": "http://ld.nice.org.uk/ns/bnf/",
		"nicebnf": "http://ld.nice.org.uk/ns/bnf#",
		"route": "http://ld.nice.org.uk/ns/bnf/Route#",
		"patientGroup": "http://ld.nice.org.uk/ns/bnf/PatientGroup#",
		"indication": "http://ld.nice.org.uk/ns/bnf/Indication#",
		"sideEffect": "http://ld.nice.org.uk/ns/bnf/SideEffect#",
		"classification": "http://ld.nice.org.uk/ns/bnf/Classification#",
		"isLinkedFrom": {
			"@container": "@set"
		},
		"hasInteraction": {
			"@container": "@set"
		},
		"hasMessage": {
			"@container": "@set"
		},
		"hasInteractionList": {
			"@container": "@set"
		},
		"isInteractionListOf": {
			"@container": "@set"
		}
	},
	"@graph": [
		{
			"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2",
			"@type": "InteractionList",
			"hasInteraction": [
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935296",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935296_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"aldesleukin\" outputclass=\"int-drug\">aldesleukin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  aldesleukin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "1",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aldesleukin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935297",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935297_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"amiodarone\" outputclass=\"int-drug\">amiodarone</ph> can increase the risk of peripheral neuropathy.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  amiodarone  can increase the risk of peripheral neuropathy. \n\n"
						}
					],
					"hasOrder": "2",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amiodarone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935298",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935298_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"amsacrine\" outputclass=\"int-drug\">amsacrine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  amsacrine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "3",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amsacrine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935299",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935299_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"arsenic trioxide\" outputclass=\"int-drug\">arsenic trioxide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  arsenic trioxide  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "4",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Arsenic trioxide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935300",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935300_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"asparaginase\" outputclass=\"int-drug\">asparaginase</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  asparaginase  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "5",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Asparaginase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935301",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935301_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"axitinib\" outputclass=\"int-drug\">axitinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  axitinib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "6",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Axitinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935302",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935302_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"azacitidine\" outputclass=\"int-drug\">azacitidine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  azacitidine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "7",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Azacitidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935303",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935303_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"azathioprine\" outputclass=\"int-drug\">azathioprine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  azathioprine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "8",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Azathioprine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935304",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935304_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"Bacillus Calmette-Guérin vaccine\" outputclass=\"int-drug\">Bacillus Calmette-Guérin vaccine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of generalised infection (possibly life-threatening) when given with</ph> <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph>. <ph outputclass=\"int-action\">UKHSA advises avoid (refer to Green Book)</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Bacillus Calmette-Guérin vaccine   is predicted to   increase   the risk of generalised infection (possibly life-threatening) when given with   brentuximab vedotin .  UKHSA advises avoid (refer to Green Book) .    \n\n"
						}
					],
					"hasOrder": "9",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bacillus Calmette-Guérin vaccine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935305",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935305_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"belatacept\" outputclass=\"int-drug\">belatacept</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  belatacept  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "10",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Belatacept</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935306",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935306_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"bendamustine\" outputclass=\"int-drug\">bendamustine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  bendamustine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "11",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bendamustine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935307",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935307_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"bexarotene\" outputclass=\"int-drug\">bexarotene</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  bexarotene  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "12",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bexarotene</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935308",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935308_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"bleomycin\" outputclass=\"int-drug\">bleomycin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  bleomycin  can increase the risk of myelosuppression. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935308_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">Brentuximab vedotin</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of pulmonary toxicity when given with</ph> <ph otherprops=\"bleomycin\" outputclass=\"int-drug\">bleomycin</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Brentuximab vedotin   increases   the risk of pulmonary toxicity when given with   bleomycin .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "13",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bleomycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935309",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935309_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"bortezomib\" outputclass=\"int-drug\">bortezomib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  bortezomib  can increase the risk of myelosuppression. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935309_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"bortezomib\" outputclass=\"int-drug\">bortezomib</ph> can increase the risk of peripheral neuropathy.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  brentuximab vedotin  and  bortezomib  can increase the risk of peripheral neuropathy. \n\n"
						}
					],
					"hasOrder": "14",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bortezomib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935310",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935310_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"bosutinib\" outputclass=\"int-drug\">bosutinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  bosutinib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "15",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bosutinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935311",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935311_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"busulfan\" outputclass=\"int-drug\">busulfan</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  busulfan  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "16",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Busulfan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935312",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935312_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"cabazitaxel\" outputclass=\"int-drug\">cabazitaxel</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  cabazitaxel  can increase the risk of myelosuppression. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935312_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"cabazitaxel\" outputclass=\"int-drug\">cabazitaxel</ph> can increase the risk of peripheral neuropathy.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  brentuximab vedotin  and  cabazitaxel  can increase the risk of peripheral neuropathy. \n\n"
						}
					],
					"hasOrder": "17",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cabazitaxel</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935313",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935313_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"cabozantinib\" outputclass=\"int-drug\">cabozantinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  cabozantinib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "18",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cabozantinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935314",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935314_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"capecitabine\" outputclass=\"int-drug\">capecitabine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  capecitabine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "19",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Capecitabine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935315",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935315_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"carbamazepine\" outputclass=\"int-drug\">Carbamazepine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the effects of</ph> <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Carbamazepine   is predicted to   decrease   the effects of   brentuximab vedotin .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "20",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Carbamazepine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935316",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935316_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"carboplatin\" outputclass=\"int-drug\">carboplatin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  carboplatin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "21",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Carboplatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935317",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935317_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"carfilzomib\" outputclass=\"int-drug\">carfilzomib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  carfilzomib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "22",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Carfilzomib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935318",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935318_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"carmustine\" outputclass=\"int-drug\">carmustine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  carmustine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "23",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Carmustine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935319",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935319_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"ceritinib\" outputclass=\"int-drug\">ceritinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  ceritinib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "24",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ceritinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935320",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935320_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"chlorambucil\" outputclass=\"int-drug\">chlorambucil</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  chlorambucil  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "25",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chlorambucil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935321",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935321_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"cisplatin\" outputclass=\"int-drug\">cisplatin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  cisplatin  can increase the risk of myelosuppression. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935321_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"cisplatin\" outputclass=\"int-drug\">cisplatin</ph> can increase the risk of peripheral neuropathy.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  brentuximab vedotin  and  cisplatin  can increase the risk of peripheral neuropathy. \n\n"
						}
					],
					"hasOrder": "26",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cisplatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935322",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935322_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"cladribine\" outputclass=\"int-drug\">cladribine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  cladribine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "27",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cladribine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935323",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935323_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"clarithromycin\" outputclass=\"int-drug\">Clarithromycin</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of neutropenia when given with</ph> <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Clarithromycin   increases   the risk of neutropenia when given with   brentuximab vedotin .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "28",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clarithromycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935324",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935324_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"clofarabine\" outputclass=\"int-drug\">clofarabine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  clofarabine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "29",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clofarabine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935325",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935325_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"crisantaspase\" outputclass=\"int-drug\">crisantaspase</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  crisantaspase  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "30",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Crisantaspase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935326",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935326_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"cyclophosphamide\" outputclass=\"int-drug\">cyclophosphamide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  cyclophosphamide  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "31",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cyclophosphamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935327",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935327_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"cytarabine\" outputclass=\"int-drug\">cytarabine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  cytarabine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "32",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cytarabine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935328",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935328_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"dacarbazine\" outputclass=\"int-drug\">dacarbazine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  dacarbazine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "33",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dacarbazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935329",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935329_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"dactinomycin\" outputclass=\"int-drug\">dactinomycin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  dactinomycin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "34",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dactinomycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935330",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935330_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"dasatinib\" outputclass=\"int-drug\">dasatinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  dasatinib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "35",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dasatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935331",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935331_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"daunorubicin\" outputclass=\"int-drug\">daunorubicin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  daunorubicin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "36",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Daunorubicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935332",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935332_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"decitabine\" outputclass=\"int-drug\">decitabine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  decitabine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "37",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Decitabine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935333",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935333_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"dexrazoxane\" outputclass=\"int-drug\">dexrazoxane</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  dexrazoxane  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "38",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dexrazoxane</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935334",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935334_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"disulfiram\" outputclass=\"int-drug\">disulfiram</ph> can increase the risk of peripheral neuropathy.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  disulfiram  can increase the risk of peripheral neuropathy. \n\n"
						}
					],
					"hasOrder": "39",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Disulfiram</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935335",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935335_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"docetaxel\" outputclass=\"int-drug\">docetaxel</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  docetaxel  can increase the risk of myelosuppression. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935335_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"docetaxel\" outputclass=\"int-drug\">docetaxel</ph> can increase the risk of peripheral neuropathy.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  brentuximab vedotin  and  docetaxel  can increase the risk of peripheral neuropathy. \n\n"
						}
					],
					"hasOrder": "40",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Docetaxel</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935336",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935336_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"doxorubicin\" outputclass=\"int-drug\">doxorubicin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  doxorubicin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "41",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Doxorubicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935337",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935337_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-drug\">Dronedarone</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of neutropenia when given with</ph> <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   increases   the risk of neutropenia when given with   brentuximab vedotin .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "42",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dronedarone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935338",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935338_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"epirubicin\" outputclass=\"int-drug\">epirubicin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  epirubicin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "43",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Epirubicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935339",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935339_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"eribulin\" outputclass=\"int-drug\">eribulin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  eribulin  can increase the risk of myelosuppression. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935339_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"eribulin\" outputclass=\"int-drug\">eribulin</ph> can increase the risk of peripheral neuropathy.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  brentuximab vedotin  and  eribulin  can increase the risk of peripheral neuropathy. \n\n"
						}
					],
					"hasOrder": "44",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eribulin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935340",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935340_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"estramustine\" outputclass=\"int-drug\">estramustine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  estramustine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "45",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Estramustine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935341",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935341_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"etoposide\" outputclass=\"int-drug\">etoposide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  etoposide  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "46",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Etoposide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935342",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935342_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"fludarabine\" outputclass=\"int-drug\">fludarabine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  fludarabine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "47",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fludarabine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935343",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935343_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"fluorouracil\" outputclass=\"int-drug\">fluorouracil</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  fluorouracil  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "48",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluorouracil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935344",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935344_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"fosphenytoin\" outputclass=\"int-drug\">fosphenytoin</ph> can increase the risk of peripheral neuropathy.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  fosphenytoin  can increase the risk of peripheral neuropathy. \n\n"
						}
					],
					"hasOrder": "49",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fosphenytoin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935345",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935345_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"ganciclovir\" outputclass=\"int-drug\">ganciclovir</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  ganciclovir  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "50",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ganciclovir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935346",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935346_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"gemcitabine\" outputclass=\"int-drug\">gemcitabine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  gemcitabine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "51",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Gemcitabine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935347",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935347_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"gemtuzumab ozogamicin\" outputclass=\"int-drug\">gemtuzumab ozogamicin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  gemtuzumab ozogamicin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "52",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Gemtuzumab ozogamicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935348",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935348_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"herpes-zoster vaccine, live\" outputclass=\"int-drug\">Herpes-zoster vaccine, live</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of generalised infection (possibly life-threatening) when given with</ph> <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph>. <ph outputclass=\"int-action\">UKHSA advises avoid (refer to Green Book)</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Herpes-zoster vaccine, live   is predicted to   increase   the risk of generalised infection (possibly life-threatening) when given with   brentuximab vedotin .  UKHSA advises avoid (refer to Green Book) .    \n\n"
						}
					],
					"hasOrder": "53",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Herpes-zoster vaccine, live</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935349",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935349_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"hydroxycarbamide\" outputclass=\"int-drug\">hydroxycarbamide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  hydroxycarbamide  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "54",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydroxycarbamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935350",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935350_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"ibrutinib\" outputclass=\"int-drug\">ibrutinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  ibrutinib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "55",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ibrutinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935351",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935351_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"idarubicin\" outputclass=\"int-drug\">idarubicin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  idarubicin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "56",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Idarubicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935352",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935352_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"ifosfamide\" outputclass=\"int-drug\">ifosfamide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  ifosfamide  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "57",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ifosfamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935353",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935353_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"imatinib\" outputclass=\"int-drug\">imatinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  imatinib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "58",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Imatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935354",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935354_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"influenza vaccine (live)\" outputclass=\"int-drug\">Influenza vaccine (live)</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of generalised infection (possibly life-threatening) when given with</ph> <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph>. <ph outputclass=\"int-action\">UKHSA advises avoid (refer to Green Book)</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Influenza vaccine (live)   is predicted to   increase   the risk of generalised infection (possibly life-threatening) when given with   brentuximab vedotin .  UKHSA advises avoid (refer to Green Book) .    \n\n"
						}
					],
					"hasOrder": "59",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Influenza vaccine (live)</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935355",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935355_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"irinotecan\" outputclass=\"int-drug\">irinotecan</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  irinotecan  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "60",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Irinotecan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935356",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935356_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"isoniazid\" outputclass=\"int-drug\">isoniazid</ph> can increase the risk of peripheral neuropathy.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  isoniazid  can increase the risk of peripheral neuropathy. \n\n"
						}
					],
					"hasOrder": "61",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Isoniazid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935357",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935357_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"itraconazole\" outputclass=\"int-drug\">Itraconazole</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of neutropenia when given with</ph> <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Itraconazole   increases   the risk of neutropenia when given with   brentuximab vedotin .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "62",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Itraconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935358",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935358_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ketoconazole\" outputclass=\"int-drug\">Ketoconazole</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of neutropenia when given with</ph> <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ketoconazole   increases   the risk of neutropenia when given with   brentuximab vedotin .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "63",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ketoconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935359",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935359_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"lamivudine\" outputclass=\"int-drug\">lamivudine</ph> can increase the risk of peripheral neuropathy.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  lamivudine  can increase the risk of peripheral neuropathy. \n\n"
						}
					],
					"hasOrder": "64",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lamivudine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935360",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935360_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"leflunomide\" outputclass=\"int-drug\">leflunomide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  leflunomide  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "65",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Leflunomide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935361",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935361_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"lenalidomide\" outputclass=\"int-drug\">lenalidomide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  lenalidomide  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "66",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lenalidomide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935362",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935362_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"lomustine\" outputclass=\"int-drug\">lomustine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  lomustine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "67",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lomustine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935363",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935363_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"lopinavir\" outputclass=\"int-drug\">Lopinavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of neutropenia when given with</ph> <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Lopinavir   is predicted to   increase   the risk of neutropenia when given with   brentuximab vedotin .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "68",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lopinavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935364",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935364_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"measles, mumps and rubella vaccine, live\" outputclass=\"int-drug\">Measles, mumps and rubella vaccine, live</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of generalised infection (possibly life-threatening) when given with</ph> <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph>. <ph outputclass=\"int-action\">UKHSA advises avoid (refer to Green Book)</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Measles, mumps and rubella vaccine, live   is predicted to   increase   the risk of generalised infection (possibly life-threatening) when given with   brentuximab vedotin .  UKHSA advises avoid (refer to Green Book) .    \n\n"
						}
					],
					"hasOrder": "69",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Measles, mumps and rubella vaccine, live</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935365",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935365_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"melphalan\" outputclass=\"int-drug\">melphalan</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  melphalan  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "70",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Melphalan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935366",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935366_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"mercaptopurine\" outputclass=\"int-drug\">mercaptopurine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  mercaptopurine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "71",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mercaptopurine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935367",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935367_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"methotrexate\" outputclass=\"int-drug\">methotrexate</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  methotrexate  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "72",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Methotrexate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935368",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935368_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"metronidazole\" outputclass=\"int-drug\">metronidazole</ph> can increase the risk of peripheral neuropathy.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  metronidazole  can increase the risk of peripheral neuropathy. \n\n"
						}
					],
					"hasOrder": "73",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Metronidazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935369",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935369_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"mifamurtide\" outputclass=\"int-drug\">mifamurtide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  mifamurtide  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "74",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mifamurtide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935370",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935370_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"mitomycin\" outputclass=\"int-drug\">mitomycin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  mitomycin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "75",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mitomycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935371",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935371_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"mitotane\" outputclass=\"int-drug\">mitotane</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  mitotane  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "76",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mitotane</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935372",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935372_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"mitoxantrone\" outputclass=\"int-drug\">mitoxantrone</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  mitoxantrone  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "77",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mitoxantrone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935373",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935373_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"nelarabine\" outputclass=\"int-drug\">nelarabine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  nelarabine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "78",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nelarabine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935374",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935374_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"nilotinib\" outputclass=\"int-drug\">nilotinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  nilotinib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "79",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nilotinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935375",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935375_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"niraparib\" outputclass=\"int-drug\">niraparib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  niraparib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "80",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Niraparib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935376",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935376_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"nitrofurantoin\" outputclass=\"int-drug\">nitrofurantoin</ph> can increase the risk of peripheral neuropathy.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  nitrofurantoin  can increase the risk of peripheral neuropathy. \n\n"
						}
					],
					"hasOrder": "81",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nitrofurantoin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935377",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935377_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"olaparib\" outputclass=\"int-drug\">olaparib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  olaparib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "82",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Olaparib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935378",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935378_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"oxaliplatin\" outputclass=\"int-drug\">oxaliplatin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  oxaliplatin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "83",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Oxaliplatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935379",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935379_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"paclitaxel\" outputclass=\"int-drug\">paclitaxel</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  paclitaxel  can increase the risk of myelosuppression. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935379_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"paclitaxel\" outputclass=\"int-drug\">paclitaxel</ph> can increase the risk of peripheral neuropathy.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  brentuximab vedotin  and  paclitaxel  can increase the risk of peripheral neuropathy. \n\n"
						}
					],
					"hasOrder": "84",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Paclitaxel</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935380",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935380_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"palbociclib\" outputclass=\"int-drug\">palbociclib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  palbociclib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "85",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Palbociclib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935381",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935381_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"panobinostat\" outputclass=\"int-drug\">panobinostat</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  panobinostat  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "86",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Panobinostat</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935382",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935382_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"pegaspargase\" outputclass=\"int-drug\">pegaspargase</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  pegaspargase  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "87",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pegaspargase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935383",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935383_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"peginterferon alfa\" outputclass=\"int-drug\">peginterferon alfa</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  peginterferon alfa  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "88",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Peginterferon alfa</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935384",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935384_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"pemetrexed\" outputclass=\"int-drug\">pemetrexed</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  pemetrexed  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "89",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pemetrexed</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935385",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935385_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"pentostatin\" outputclass=\"int-drug\">pentostatin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  pentostatin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "90",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pentostatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935386",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935386_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"phenytoin\" outputclass=\"int-drug\">phenytoin</ph> can increase the risk of peripheral neuropathy.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  phenytoin  can increase the risk of peripheral neuropathy. \n\n"
						}
					],
					"hasOrder": "91",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenytoin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935387",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935387_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"pixantrone\" outputclass=\"int-drug\">pixantrone</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  pixantrone  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "92",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pixantrone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935388",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935388_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"pomalidomide\" outputclass=\"int-drug\">pomalidomide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  pomalidomide  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "93",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pomalidomide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935389",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935389_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"procarbazine\" outputclass=\"int-drug\">procarbazine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  procarbazine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "94",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Procarbazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935390",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935390_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"raltitrexed\" outputclass=\"int-drug\">raltitrexed</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  raltitrexed  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "95",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Raltitrexed</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935391",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935391_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"regorafenib\" outputclass=\"int-drug\">regorafenib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  regorafenib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "96",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Regorafenib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935392",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935392_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"ribociclib\" outputclass=\"int-drug\">ribociclib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  ribociclib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "97",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ribociclib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935393",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935393_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"rifampicin\" outputclass=\"int-drug\">Rifampicin</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the effects of</ph> <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Rifampicin   decreases   the effects of   brentuximab vedotin .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "98",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rifampicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935394",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935394_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ritonavir\" outputclass=\"int-drug\">Ritonavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of neutropenia when given with</ph> <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ritonavir   is predicted to   increase   the risk of neutropenia when given with   brentuximab vedotin .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "99",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ritonavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935395",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935395_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"ropeginterferon alfa\" outputclass=\"int-drug\">ropeginterferon alfa</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  ropeginterferon alfa  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "100",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ropeginterferon alfa</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935396",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935396_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"rotavirus vaccine\" outputclass=\"int-drug\">Rotavirus vaccine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of generalised infection (possibly life-threatening) when given with</ph> <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph>. <ph outputclass=\"int-action\">UKHSA advises avoid (refer to Green Book)</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Rotavirus vaccine   is predicted to   increase   the risk of generalised infection (possibly life-threatening) when given with   brentuximab vedotin .  UKHSA advises avoid (refer to Green Book) .    \n\n"
						}
					],
					"hasOrder": "101",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rotavirus vaccine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935397",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935397_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"rucaparib\" outputclass=\"int-drug\">rucaparib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  rucaparib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "102",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rucaparib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935398",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935398_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"ruxolitinib\" outputclass=\"int-drug\">ruxolitinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  ruxolitinib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "103",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ruxolitinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935399",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935399_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"sorafenib\" outputclass=\"int-drug\">sorafenib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  sorafenib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "104",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sorafenib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935400",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935400_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"streptozocin\" outputclass=\"int-drug\">streptozocin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  streptozocin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "105",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Streptozocin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935401",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935401_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"sulfasalazine\" outputclass=\"int-drug\">sulfasalazine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  sulfasalazine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "106",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sulfasalazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935402",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935402_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"sunitinib\" outputclass=\"int-drug\">sunitinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  sunitinib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "107",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sunitinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935403",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935403_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"talazoparib\" outputclass=\"int-drug\">talazoparib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  talazoparib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "108",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Talazoparib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935404",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935404_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"tegafur\" outputclass=\"int-drug\">tegafur</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  tegafur  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "109",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tegafur</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935405",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935405_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"temozolomide\" outputclass=\"int-drug\">temozolomide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  temozolomide  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "110",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Temozolomide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935406",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935406_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"temsirolimus\" outputclass=\"int-drug\">temsirolimus</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  temsirolimus  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "111",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Temsirolimus</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935407",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935407_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"thalidomide\" outputclass=\"int-drug\">thalidomide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  thalidomide  can increase the risk of myelosuppression. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935407_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"thalidomide\" outputclass=\"int-drug\">thalidomide</ph> can increase the risk of peripheral neuropathy.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  brentuximab vedotin  and  thalidomide  can increase the risk of peripheral neuropathy. \n\n"
						}
					],
					"hasOrder": "112",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Thalidomide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935408",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935408_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"thiotepa\" outputclass=\"int-drug\">thiotepa</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  thiotepa  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "113",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Thiotepa</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935409",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935409_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"tioguanine\" outputclass=\"int-drug\">tioguanine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  tioguanine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "114",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tioguanine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935410",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935410_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"topotecan\" outputclass=\"int-drug\">topotecan</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  topotecan  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "115",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Topotecan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935411",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935411_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"trabectedin\" outputclass=\"int-drug\">trabectedin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  trabectedin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "116",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trabectedin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935412",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935412_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"treosulfan\" outputclass=\"int-drug\">treosulfan</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  treosulfan  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "117",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Treosulfan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935413",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935413_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"typhoid vaccine, oral\" outputclass=\"int-drug\">Typhoid vaccine, oral</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of generalised infection (possibly life-threatening) when given with</ph> <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph>. <ph outputclass=\"int-action\">UKHSA advises avoid (refer to Green Book)</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Typhoid vaccine, oral   is predicted to   increase   the risk of generalised infection (possibly life-threatening) when given with   brentuximab vedotin .  UKHSA advises avoid (refer to Green Book) .    \n\n"
						}
					],
					"hasOrder": "118",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Typhoid vaccine, oral</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935414",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935414_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"valganciclovir\" outputclass=\"int-drug\">valganciclovir</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  valganciclovir  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "119",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Valganciclovir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935415",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935415_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"varicella-zoster vaccine\" outputclass=\"int-drug\">Varicella-zoster vaccine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of generalised infection (possibly life-threatening) when given with</ph> <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph>. <ph outputclass=\"int-action\">UKHSA advises avoid (refer to Green Book)</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Varicella-zoster vaccine   is predicted to   increase   the risk of generalised infection (possibly life-threatening) when given with   brentuximab vedotin .  UKHSA advises avoid (refer to Green Book) .    \n\n"
						}
					],
					"hasOrder": "120",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Varicella-zoster vaccine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935416",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935416_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"vinblastine\" outputclass=\"int-drug\">vinblastine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  vinblastine  can increase the risk of myelosuppression. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935416_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"vinblastine\" outputclass=\"int-drug\">vinblastine</ph> can increase the risk of peripheral neuropathy.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  brentuximab vedotin  and  vinblastine  can increase the risk of peripheral neuropathy. \n\n"
						}
					],
					"hasOrder": "121",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vinblastine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935417",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935417_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"vincristine\" outputclass=\"int-drug\">vincristine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  vincristine  can increase the risk of myelosuppression. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935417_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"vincristine\" outputclass=\"int-drug\">vincristine</ph> can increase the risk of peripheral neuropathy.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  brentuximab vedotin  and  vincristine  can increase the risk of peripheral neuropathy. \n\n"
						}
					],
					"hasOrder": "122",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vincristine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935418",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935418_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"vindesine\" outputclass=\"int-drug\">vindesine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  vindesine  can increase the risk of myelosuppression. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935418_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"vindesine\" outputclass=\"int-drug\">vindesine</ph> can increase the risk of peripheral neuropathy.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  brentuximab vedotin  and  vindesine  can increase the risk of peripheral neuropathy. \n\n"
						}
					],
					"hasOrder": "123",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vindesine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935419",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935419_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"vinflunine\" outputclass=\"int-drug\">vinflunine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  vinflunine  can increase the risk of myelosuppression. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935419_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"vinflunine\" outputclass=\"int-drug\">vinflunine</ph> can increase the risk of peripheral neuropathy.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  brentuximab vedotin  and  vinflunine  can increase the risk of peripheral neuropathy. \n\n"
						}
					],
					"hasOrder": "124",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vinflunine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935420",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935420_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"vinorelbine\" outputclass=\"int-drug\">vinorelbine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  brentuximab vedotin  and  vinorelbine  can increase the risk of myelosuppression. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935420_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph> and <ph otherprops=\"vinorelbine\" outputclass=\"int-drug\">vinorelbine</ph> can increase the risk of peripheral neuropathy.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  brentuximab vedotin  and  vinorelbine  can increase the risk of peripheral neuropathy. \n\n"
						}
					],
					"hasOrder": "125",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vinorelbine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935421",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2#bnf_i1643857935421_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"yellow fever vaccine, live\" outputclass=\"int-drug\">Yellow fever vaccine, live</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of generalised infection (possibly life-threatening) when given with</ph> <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-heading-drug\">brentuximab vedotin</ph>. <ph outputclass=\"int-action\">UKHSA advises avoid (refer to Green Book)</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Yellow fever vaccine, live   is predicted to   increase   the risk of generalised infection (possibly life-threatening) when given with   brentuximab vedotin .  UKHSA advises avoid (refer to Green Book) .    \n\n"
						}
					],
					"hasOrder": "126",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Yellow fever vaccine, live</title>"
					}
				}
			],
			"hasSearchLabel": " Brentuximab vedotin  | Interactions",
			"hasSearchLink": {
				"@id": "http://bnf.nice.org.uk/interaction/brentuximab-vedotin-2.html"
			},
			"hasTitle": {
				"@type": "rdf:XMLLiteral",
				"@value": "<title> Brentuximab vedotin </title>"
			},
			"rdfs:label": "brentuximab vedotin"
		}
	]
}